Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer

Authors: TI Andersen, E Skovlund, IK Bukholm, U Jacobsen, R Kåresen, B Erikstein, J Nesland, A-L Børresen-Dale

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

Activation of the HER-2 proto-oncogene and inactivation of the TP53 tumour-suppressor gene belong to the most common genetic changes in human breast carcinomas. Both appear to be of prognostic significance, at least in patients with node-positive disease. The relevance of these changes in node-negative disease, however, still remains uncertain. Moreover, the relationship between HER-2 and TP53 status remains to be fully clarified. …
Metadata
Title
HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
Authors
TI Andersen
E Skovlund
IK Bukholm
U Jacobsen
R Kåresen
B Erikstein
J Nesland
A-L Børresen-Dale
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr158

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Oral presentation

Molecular control of apoptosis in the breast

Meeting abstract

Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients

Oral presentation

Other cancers in BRCA1 and BRCA2 mutation carriers: implications for counselling and follow up

Meeting abstract

Molecular analyses of human breast cancer metastasis: genetic markers of progression

Oral presentation

Characterisation of micrometastatic tumor cells

Meeting abstract

kConFab: a unique Australasian research initiative for familial breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits